Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06119672
Other study ID # 311122
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 1, 2023
Est. completion date December 30, 2023

Study information

Verified date November 2023
Source October 6 University
Contact Amira Abdelwhab, lecturer
Phone 01007647877
Email amira.abdelwhab.dent@o6u.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Oral lichen planus patients who will meet inclusion criteria will be divided into 2 groups -The intervention group (Group P): This group will be randomly allocated to take one capsule twice daily during meal time at morning and evening of probiotics complex obtained from Biovea for 4 -week study period. Moreover, patients in this group will be instructed to apply clobetasole propionate in orabase gel 2 times daily for 4 weeks. Patients will receive their supply of the gel and probiotics every 2 weeks. The control group (Group B): This group will be randomly allocated to apply clobetasol propionate in orabase gel 4 times daily after meal times and before sleeping for 4 weeks. At the 3rd week this group will be instructed to apply miconazole gel 4 times daily as a prophylaxis for two weeks. Salivary sample collection: Unstimulated salivary sample was collected from all participants twice , once at baseline and another time after 4 weeks from the study period. Saliva was collected in graduated clear test tubes to be used in the evaluation of candidal counts before and after treatment . Patient's visits was at baseline, 2 weeks and 4 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date December 30, 2023
Est. primary completion date October 30, 2023
Accepts healthy volunteers No
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria: - Patients who are diagnosed with symptomatic lichen planus whether bullous erosive or erythematous oral lichen planus. - Male or female patient with age range between 20-75 years old were included. - medically free individuals Exclusion Criteria: - the use of systemic antibiotics, corticosteroids or immunosuppressive agents within four weeks prior to enrollment in the study. - Pregnant females - patients with history of systemic disorder affecting the immune system - active liver diseases and cancer - allergy or intolerance to probiotics. - any other oral lesions

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Probiotic Blend Oral capsules
probtiotic bend oral tablets from biovia will be adminestrated containing 4 strains ( twice daily) in addition to topical clobetasol application twice daily
Corticosteroids for Local Oral Treatment
topical clobetasol probionate in orabase application 4 times daily

Locations

Country Name City State
Egypt Cairo University Cairo

Sponsors (2)

Lead Sponsor Collaborator
October 6 University Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary size wound thongprasom scale 0 , 2 weeks and 4 weeks
Primary Pain in oral cavity Numerical rating scale (0-10) 0= minimal pain 10 unbearable pain 0 , 2 weeks and 4 weeks
Secondary candidal load assessment culturing technique in CFU unit 0 and 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05997173 - The Regulatory Role of Immune Response in Oral Lichen Planus
Completed NCT02443311 - Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus Phase 4
Completed NCT00484250 - Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other Phase 2
Completed NCT03682562 - Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
Completed NCT04193748 - Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial) Phase 4
Completed NCT04153266 - Oral Epithelial Dysplasia Informational Needs Questionnaire
Recruiting NCT06135805 - Impact of Fluocinonide 0,05% in Oral Lichen Planus N/A
Completed NCT04289233 - Molecular & Cellular Characterisation of Oral Lichen Planus
Completed NCT04293718 - Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival Biopsy
Completed NCT00525421 - A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus Phase 2
Not yet recruiting NCT04091698 - Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial Phase 1
Completed NCT03386643 - Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus Phase 2
Withdrawn NCT03836885 - Apremilast - Oral Lichen Planus Trial Phase 2
Completed NCT05730855 - Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
Completed NCT03257228 - The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2) N/A
Recruiting NCT03026478 - Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus Phase 2
Completed NCT02834520 - Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus N/A
Completed NCT02858297 - Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus Phase 4
Completed NCT02106468 - The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus Phase 2
Recruiting NCT00737854 - Free Soft Tissue Graft in Treatment of Oral Lichen Planus Phase 1